[HTML][HTML] Mutation in FBXO32 causes dilated cardiomyopathy through up-regulation of ER-stress mediated apoptosis

N Al-Yacoub, D Colak, SA Mahmoud… - Communications …, 2021 - nature.com
N Al-Yacoub, D Colak, SA Mahmoud, M Hammonds, K Muhammed, O Al-Harazi, AM Assiri
Communications Biology, 2021nature.com
Endoplasmic reticulum (ER) stress induction of cell death is implicated in cardiovascular
diseases. Sustained activation of ER-stress induces the unfolded protein response (UPR)
pathways, which in turn activate three major effector proteins. We previously reported a
missense homozygous mutation in FBXO32 (MAFbx, Atrogin-1) causing advanced heart
failure by impairing autophagy. In the present study, we performed transcriptional profiling
and biochemical assays, which unexpectedly revealed a reduced activation of UPR effectors …
Abstract
Endoplasmic reticulum (ER) stress induction of cell death is implicated in cardiovascular diseases. Sustained activation of ER-stress induces the unfolded protein response (UPR) pathways, which in turn activate three major effector proteins. We previously reported a missense homozygous mutation in FBXO32 (MAFbx, Atrogin-1) causing advanced heart failure by impairing autophagy. In the present study, we performed transcriptional profiling and biochemical assays, which unexpectedly revealed a reduced activation of UPR effectors in patient mutant hearts, while a strong up-regulation of the CHOP transcription factor and of its target genes are observed. Expression of mutant FBXO32 in cells is sufficient to induce CHOP-associated apoptosis, to increase the ATF2 transcription factor and to impair ATF2 ubiquitination. ATF2 protein interacts with FBXO32 in the human heart and its expression is especially high in FBXO32 mutant hearts. These findings provide a new underlying mechanism for FBXO32-mediated cardiomyopathy, implicating abnormal activation of CHOP. These results suggest alternative non-canonical pathways of CHOP activation that could be considered to develop new therapeutic targets for the treatment of FBXO32-associated DCM.
nature.com